Xylazine: What It Is, and Why It's Changing Overdose Response
Not an opioid. Not reversed by naloxone. Increasingly in the fentanyl supply — and leaving characteristic wounds.
Body: [Clear explainer: xylazine is a veterinary sedative (“tranq”), not a scheduled drug, appearing across the illicit opioid supply. Naloxone reverses the fentanyl component of an overdose but not the xylazine sedation — supportive breathing and 911 still required. The wound pattern is characteristic (necrotic ulcers unrelated to injection site). Test strip availability is expanding. Includes geographic spread data, treatment implications, and regulatory response. 900 words.]
Sources Cited
- 01.A
- 02.A
Filed Under
NaloxoneOverdosePeer-Reviewed Research
Continue reading
More from this section
69,973 Deaths. The Number That Proves Harm Reduction Works—and the Policy Quietly Undoing It.
CDC provisional data projects 69,973 overdose deaths for 2025—a 13.9% decline. The same spring, SAMHSA ended federal funding for fentanyl test strips. The drug supply has never been more dangerous.
Harm ReductionResponding to the Emerging Threat of Xylazine
On April 24, SAMHSA banned federal funding for fentanyl, xylazine, and medetomidine test strips for public distribution — precisely as the June 2026 Labcorp report shows medetomidine in 91% of Philadelphia's fentanyl supply. The policy contradiction that kills people who use drugs.
Harm ReductionThe Drug Inside the Drug: How Medetomidine Is Breaking Every Overdose Response Playbook
Medetomidine, a veterinary sedative 200 times more potent than xylazine, has displaced xylazine in Philadelphia's fentanyl supply and is confirmed in nine states. It produces sedation that naloxone cannot reverse, withdrawal that requires ICU-level care in 91% of hospitalized patients, and clinical presentations that emergency departments are consistently misidentifying.